^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Efficacy of immune checkpoint inhibitors in patients with non–small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.

    Published date:
    05/26/2022
    Excerpt:
    NSCLC patients carrying ERBB2 ex20ins demonstrated worse clinical outcome under ICI treatment…
    DOI:
    10.1200/JCO.2022.40.16_suppl.2591